Clinical Trials Logo

Liver Cancer clinical trials

View clinical trials related to Liver Cancer.

Filter by:

NCT ID: NCT04341012 Completed - COVID19 Clinical Trials

Breath Analysis Based Disease Biomarkers of COVID-19 and Other Diseases

Start date: September 10, 2019
Phase:
Study type: Observational

The purpose of the study is to develop a clinical test based on breath analysis that can be used for disease diagnosis or prognosis.

NCT ID: NCT04272619 Completed - Liver Cancer Clinical Trials

Liver Cancer Community Education

Start date: February 11, 2020
Phase: N/A
Study type: Interventional

This study proposes to bridge the gap between evidence and action and combat rising liver cancer rates attributed to Hepatitis B and C infection in Philadelphia by identifying neighborhoods with higher than expected rates of liver cancer and related risk factors and administering an educational intervention about liver cancer and neighborhood health in those communities, working with existing community partners at Fox Chase Cancer Center.

NCT ID: NCT04269499 Completed - Liver Cancer Clinical Trials

Real-time Imaging of Holmium Radioembolization: a Feasibility Study

Emeritus
Start date: November 11, 2019
Phase: N/A
Study type: Interventional

This is a feasibility study in which patients with liver tumors are treated with holmium radioembolization under real time MR imaging.

NCT ID: NCT04257240 Completed - Liver Cancer Clinical Trials

Recurrence of Liver Malignancy After Ischemia/Reperfusion Injury

annie-liver
Start date: January 1, 2000
Phase:
Study type: Observational

Severe ischemic changes of the liver remnant after hepatectomy could expedite tumor recurrence on the residual liver. Our study aimed at assessing the effect of warm ischemic/reperfusion (I/R) injuries on surgery-to-local recurrence interval and patient overall survival, during major hepatectomies under inflow and outflow vascular control.

NCT ID: NCT04106453 Completed - Surgery Clinical Trials

Navigated Laparoscopic Microwave Ablation of Tumor Mimics in Pig Liver - an Ex-vivo Trial

Start date: September 14, 2019
Phase: N/A
Study type: Interventional

In primary and secondary liver tumors microwave ablation could be an alternative to surgical resection.It could be performed laparoscopically. Under ultrasound control the microwave device is placed in the tumor.Therefore spatial orientation is challenging: the tumor is often missed and the failure rate is high. During learning curve this could lead to incomplete tumor ablation and high rate of local recurrence. Targeting systems could optimize that. The CasOne-SPOT-system is an innovative electromagnetic tracking and navigation system for laparoscopic microwave ablation. In this study targeting precision using the SPOT-System should be compared to conventional laparoscopic ultrasound-guided microwave ablation. Therefore tumor mimics (1-2cm) will be created in ex-vivo pig livers and microwave ablation will be performed ultrasound guided or ultrasound navigated. The ablation procedures will be performed by two novices and two experienced surgeons. Aim of this trial is to is to evaluate, if laparoscopic microwave ablation could be facilitated by the use of the SPOT-navigation system.

NCT ID: NCT03891654 Completed - Liver Cancer Clinical Trials

Dynamic Contrast Enhanced Computed Tomography to Assess Radiation Therapy in Liver Cancer Patients

Start date: August 1, 2019
Phase: Early Phase 1
Study type: Interventional

This is a pilot study that uses a standard of care technique, Stereotactic Body Radiation Therapy (SBRT), in combination with Dynamic Contrast Enhanced Computed Tomography (DCE-CT) to determine if perfusion changes from SBRT of liver cancer may be used for outcome assessment and prediction of prognosis.

NCT ID: NCT03888859 Completed - Clinical trials for Hepatocellular Carcinoma

ET1402L1-ARTEMIS™2 T Cells in Alpha Fetoprotein (AFP) Expressing Hepatocellular Carcinoma

Start date: December 6, 2017
Phase: Early Phase 1
Study type: Interventional

Clinical study to evaluate safety (primary objectives) and efficacy (secondary objective) of ET1402L1-ARTEMIS™2 T cells in patients with alpha fetoprotein positive (AFP+ ) hepatocellular carcinoma (HCC).

NCT ID: NCT03804593 Completed - Clinical trials for Hepatocellular Carcinoma

HCCBloodTest for Detection of Hepatocellular Carcinoma (HCC)

Start date: December 17, 2018
Phase:
Study type: Observational

This is a multi-center study to prospectively gather clinically-characterized plasma samples to determine the diagnostic performance characteristics (sensitivity and specificity) of the HCCBloodTest among patients with cirrhosis with and without HCC

NCT ID: NCT03784469 Completed - Liver Cancer Clinical Trials

Effectiveness of Positioning on Back Pain After TACE Among Patients With HCC

Start date: February 21, 2018
Phase: N/A
Study type: Interventional

Changing patients' position in the bed after TACE can decrease the level of back pain without increasing the amount of bleeding and hematoma,bring patients some comfort and relieving abdominal bloating, increase patients' satisfaction.

NCT ID: NCT03775863 Completed - Clinical trials for Liver Transplant Disorder

AFP Model and Liver Transplantation.

Start date: November 11, 2017
Phase:
Study type: Observational

Background & Aim: Presence of microvascular invasion (mvi) in the explanted liver defines a higher risk of recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT). The aim of this study is to evaluate pre LT selection models of HCC recurrence specifically in patients without mvi in the explanted liver. Methods: Three multicenter cohorts are going to be included: a Latin American, a French and an Italian cohort of consecutive adult patients with HCC a first LT performed during two different periods: 2005-2011 and 2012-2016. AFP model is going to be compared against Milan and San Francisco criteria according to each models accuracy and prediction of HCC recurrence among patients without microvascular invasion in the explanted liver considering these candidates as "Low-risk patients". Multivariate Cox regression analysis, with hazard ratios (HR) and 95% confidence intervals (CI) for 5-year recurrence is going to be done with Competing Risk Regression analysis and corresponding Subhazard Ratios (SHR).